UBQLN4 Represses Homologous Recombination and Is Overexpressed in Aggressive Tumors
Author(s) -
Ron D. Jachimowicz,
Filippo Beleggia,
Jörg Isensee,
Bhagya Bhavana Velpula,
Jonas Goergens,
Matías A. Bustos,
Markus Alexander Doll,
Anjana Shenoy,
Cintia Checa-Rodríguez,
Janica L. Wiederstein,
Keren BaranesBachar,
Christoph Bartenhagen,
Falk Hertwig,
Nizan Teper,
Tomohiko Nishi,
Anna Schmitt,
Felix Distelmaier,
HermannJosef Lüdecke,
Beate Albrecht,
Marcus Krüger,
Björn Schumacher,
Tamar Geiger,
Dave S.�B. Hoon,
Pablo Huertas,
Matthias Fischer,
Tim Hucho,
Martin Peifer,
Yael Ziv,
Hans Christian Reinhardt,
Dagmar Wieczorek,
Yosef Shiloh
Publication year - 2019
Publication title -
cell
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 26.304
H-Index - 776
eISSN - 1097-4172
pISSN - 0092-8674
DOI - 10.1016/j.cell.2018.11.024
Subject(s) - biology , homologous recombination , genome instability , parp1 , chromatin , non homologous end joining , dna repair , mutation , homologous chromosome , dna damage , genetics , cancer research , microbiology and biotechnology , chromosome instability , parp inhibitor , dna , poly adp ribose polymerase , gene , polymerase , chromosome
Genomic instability can be a hallmark of both human genetic disease and cancer. We identify a deleterious UBQLN4 mutation in families with an autosomal recessive syndrome reminiscent of genome instability disorders. UBQLN4 deficiency leads to increased sensitivity to genotoxic stress and delayed DNA double-strand break (DSB) repair. The proteasomal shuttle factor UBQLN4 is phosphorylated by ATM and interacts with ubiquitylated MRE11 to mediate early steps of homologous recombination-mediated DSB repair (HRR). Loss of UBQLN4 leads to chromatin retention of MRE11, promoting non-physiological HRR activity in vitro and in vivo. Conversely, UBQLN4 overexpression represses HRR and favors non-homologous end joining. Moreover, we find UBQLN4 overexpressed in aggressive tumors. In line with an HRR defect in these tumors, UBQLN4 overexpression is associated with PARP1 inhibitor sensitivity. UBQLN4 therefore curtails HRR activity through removal of MRE11 from damaged chromatin and thus offers a therapeutic window for PARP1 inhibitor treatment in UBQLN4-overexpressing tumors.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom